Water Leaders to Accelerate Action Towards UN Sustainable Development Goals at IWA World Water Congress 2022
12.9.2022 12:00:00 EEST | Business Wire | Press release
There are 2.3 billion people who now live in water-stressed countries and 18 million people risk being displaced by floods every year1. Against this backdrop, global water technology company Xylem (NYSE: XYL), will join water sector leaders at the IWA World Water Congress & Exhibition, to explore solutions to build water security. Xylem executives will share perspectives on actions to increase communities’ resilience to water scarcity, and strategies to accelerate the decarbonization of water networks.
The congress takes place in Copenhagen, Denmark, 11-15 September 2022. On Wednesday, September 14, Dave Flinton, Xylem’s Chief Innovation, Technology and Product Management Officer, will discuss the business models and multidisciplinary approaches needed for successful innovation in resource recovery. Learning to Dance in the Rain — How to Thrive in an Era of Climate Change, will explore actions taken to date and future trends.
Commenting on the congress, Dave Flinton said, “Technology can make communities more resilient in the face of severe weather. Through innovation and collaboration, we can modernize water systems so that communities have affordable, accessible water, and are buffered from shocks like droughts and floods.”
On Monday, September 12, Austin Alexander, Vice President, Sustainability and Social Impact at Xylem, will take part in a keynote plenary discussion – Practical Perspectives in Building Resilience into Urban Water Management. During the session, she will share insights on building urban resiliency in the face of climate change, the solutions that are available, and the importance of maintaining momentum on the UN SDGs. As water infrastructure is a contributor to greenhouse gas (GHG) emissions, Alexander will also touch on the use of technology to meaningfully reduce emissions and help transform the future of water management.
On Wednesday, September 14, Xylem’s Global Procurement Sustainability Manager, Andrea Montuori will participate in a keynote plenary session on Uniting Youth for Water. This session will examine the role of youth within the water sector, with a special focus on the UN 2023 Water Conference, taking place in March next year.
Xylem will also hold two business forums at the congress:
- On Tuesday, September 13, Joost Aloserij, Director of Business Development, Central & North Europe at Xylem, will lead a forum on Let's Redefine what's Possible for Water. Drawing on Xylem Vue, Xylem’s digital solutions platform that combines smart, connected technologies with intelligent systems and services. This session will focus on how utilities can embrace digital innovation to improve performance, reduce costs, and better serve their communities.
- On Wednesday, September 14, Alexis De Kerchove, Senior Director, Marketing and Business Development, Europe Commercial Team, will lead a forum on Road to Net Zero, alongside Austin Alexander. This session will explore the importance of decarbonization for water and wastewater utilities.
Xylem is also the proud sponsor of the IWA Climate Smart Utilities Recognition Program which aims to inspire utilities and all their stakeholders to become Climate Smart and embrace climate resilience under three key pillars for action – adaptation, mitigation, and leadership. Following a robust review, forty-two Climate Smart utilities will be honored at the IWA World Water Congress & Exhibition closing ceremony on Thursday, September 15.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com.
______________________
1
https://www.internal-displacement.org/global-report/grid2019/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005444/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom